Can Rheumatoid Arthritis Affect the Knee After Total Knee Arthroplasty?
Yes, rheumatoid arthritis absolutely continues to affect the knee after total knee arthroplasty, manifesting through disease reactivation, altered joint mechanics, ongoing systemic inflammation, and increased complication risks.
Disease Activity Persists Post-TKA
RA remains an active systemic autoimmune disease even after joint replacement. The inflammatory process does not stop simply because the joint surfaces have been replaced with prosthetic components. Research demonstrates that approximately 15% of RA patients experience reactivation of the rheumatoid process in their replaced knees at an average of 28.6 months postoperatively 1. This reactivation is particularly influenced by preoperative disease activity levels and whether adequate synovectomy was performed during surgery 1.
The underlying disease continues to require ongoing medical management with DMARDs, biologics, or JAK inhibitors to control systemic inflammation and prevent disease progression in other joints 2.
Ongoing Medication Management is Critical
Patients must continue their antirheumatic medications after TKA to control systemic disease activity. According to the 2022 ACR/AAHKS guidelines, medications should be restarted once the surgical wound shows evidence of healing, sutures/staples are removed, there is no significant swelling, erythema, or drainage, and no ongoing infection—typically around 14 days postoperatively 2.
The specific restart protocol includes:
- Conventional DMARDs (methotrexate, leflunomide, hydroxychloroquine, sulfasalazine): Resume at usual doses
- Biologics: Restart after wound healing is confirmed
- JAK inhibitors: Resume after appropriate healing interval
Failure to maintain disease control postoperatively can lead to disease flares, which occur in over 60% of patients after surgery when medications are withheld 2.
Altered Joint Mechanics and Radiographic Changes
The pattern of joint destruction in RA patients undergoing TKA has evolved significantly in recent decades. Modern RA patients receiving TKA increasingly demonstrate osteoarthritis-like radiographic features rather than classic rheumatoid patterns 3, 4. Specifically:
- Osteophyte formation has significantly increased in recent cohorts
- Medial-dominant joint space narrowing (rather than bicompartmental narrowing) is now more common
- Bone erosion and geode formation have decreased with modern DMARD therapy 4
This shift reflects better disease control with biologics and targeted synthetic DMARDs, but also indicates that RA continues to cause structural changes even with treatment 3.
Increased Complication Risks
RA patients face substantially higher perioperative and long-term complication rates compared to osteoarthritis patients:
Medical Complications
- 2.08 times higher odds of medical complications within 90 days 5
- Higher rates of pneumonia and postoperative bleeding requiring transfusion 6
- Increased risk of wound infections, pulmonary embolism, and deep vein thrombosis 6
Implant-Related Complications
- 1.30 times higher odds of implant complications 5
- 50% increased risk of periprosthetic joint infection compared to osteoarthritis patients 2
- Longer hospital stays and higher 90-day episode-of-care costs ($16,605 vs. $15,716) 5
Mortality
- 1.35 times higher odds of 1-year mortality 5
Structural and Microarchitectural Changes
RA causes distinct osteochondral alterations that persist after TKA. Micro-CT studies reveal 7:
- Larger cortical pores in both femoral and tibial components
- Lower subchondral trabecular bone fraction
- Thinner articular cartilage in remaining tissue
- Increased cortical porosity affecting implant stability
These microstructural changes can affect implant fixation and long-term stability, particularly in patients with valgus knee alignment who show the thinnest cartilage and most altered trabecular architecture 7.
Clinical Implications
Preoperative Optimization
Patients should achieve optimal disease control before elective TKA to minimize complications. This includes:
- Targeting remission or low disease activity (CDAI score)
- Optimizing nutritional status
- Addressing modifiable risk factors (smoking, diabetes control)
Postoperative Monitoring
Close surveillance is required for:
- Disease reactivation in the operated knee (pain, swelling, warmth not attributable to infection)
- Systemic disease activity requiring medication adjustment
- Infection risk, which remains elevated long-term
- Implant stability, given altered bone microarchitecture
Long-Term Disease Management
Achieving and maintaining disease remission is essential for optimal TKA outcomes. Current treatment goals include 8, 9:
- At least 50% improvement in disease activity by 3 months
- Remission or low disease activity at 6 months
- Approximately 80% of patients achieve remission or low disease activity with combination therapy including biologics or JAK inhibitors
Important Caveats
Disease activity at final follow-up does not necessarily correlate with anterior knee pain or functional outcomes in the replaced knee 10. However, systemic disease control remains crucial for overall patient health, prevention of complications, and protection of other joints.
The decision to resurface the patella during TKA remains controversial in RA patients, though long-term outcomes without patellar resurfacing appear favorable with only 9.3% incidence of anterior knee pain at 13.6-year follow-up 10.